Assuming 2016 is required, the following results were found.

  • Drug Use for Emergency Back Pain Shifts Over Time

    NATIONAL HARBOR, Md. -- Emergency department (ED) use of tramadol for back pain doubled from 2007 to 2016 in the U.S. despite an overall decrease in opioid use in that period, an analysis of National Hospital Ambulatory Medical Care Survey (NHAMCS)...

    https://mschristian.org/index.php/blog/drug-use-for-emergency-back-pain-shifts-over-time
  • Conceptual framework to study role of exercise in multiple sclerosis

    ScienceDaily. www.sciencedaily.com/releases/2018/10/181017145323.htm (accessed September 25, 2019). RELATED STORIES Sep. 14, 2016 — Cells in the immune system of patients with multiple sclerosis behave differently from those of healthy individuals....

    https://mschristian.org/index.php/articles/2-uncategorised/4542-conceptual-framework-to-study-role-of-exercise-in-multiple-sclerosis
  • Tanezumab: A Win as Last-Ditch Osteoarthritis Tx

    this agent may finally be approved after a long and rocky development road. Among 849 patients enrolled from 104 sites from 2016 to 2018 who had not responded to other oral or injectable treatments, those randomized to 5-mg tanezumab had a change on the...

    https://mschristian.org/index.php/blog/tanezumab-a-win-as-last-ditch-osteoarthritis-tx
  • A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis

    together with a resampling and critical appraisal approach. The framework was applied to estimate the MS prevalence for 2016 in Switzerland, for which four distinct data sources (Swiss MS registry, Swiss national MS treatment registry, MediService...

    https://mschristian.org/index.php/blog/a-framework-for-estimating-the-burden-of-chronic-diseases-design-and-application-in-the-context-of-multiple-sclerosis
  • High cost of MS medicines forcing patients to take 'drastic actions' - STAT

    sclerosis patients paid $15 a month average out-of-pocket costs in 2004, but that jumped to an average of $309 a month by 2016, a 20-fold increase over a 12-year period. Patients with high-deductible plans paid an average of $661 per month compared to...

    https://mschristian.org/index.php/blog/high-cost-of-ms-medicines-forcing-patients-to-take-drastic-actions-stat
  • Conceptual framework to study role of exercise in multiple sclerosis

    ScienceDaily. www.sciencedaily.com/releases/2018/10/181017145323.htm (accessed September 25, 2019). RELATED STORIES Sep. 14, 2016 — Cells in the immune system of patients with multiple sclerosis behave differently from those of healthy individuals....

    https://mschristian.org/index.php/blog/conceptual-framework-to-study-role-of-exercise-in-multiple-sclerosis
  • Tanezumab: A Win as Last-Ditch Osteoarthritis Tx

    this agent may finally be approved after a long and rocky development road. Among 849 patients enrolled from 104 sites from 2016 to 2018 who had not responded to other oral or injectable treatments, those randomized to 5-mg tanezumab had a change on the...

    https://mschristian.org/index.php/articles/2-uncategorised/10493-tanezumab-a-win-as-last-ditch-osteoarthritis-tx
  • Worldwide Genomics Markets, 2020-2027 - Comprehensive Analysis on the $31.1 Billion-Projected Industry - P&T Community

    Laboratories. Key Topics Covered Chapter 1 Research Methodology Chapter 2 Executive Summary 2.1 Genomics Market Outlook, 2016-2027 Chapter 3 Industry Outlook 3.1 Penetration & Growth Prospects Mapping 3.2 Trend Analysis 3.2.1 Application Trends 3.2.2...

    https://mschristian.org/index.php/blog/worldwide-genomics-markets-2020-2027-comprehensive-analysis-on-the-31-1-billion-projected-industry-p-t-community
  • Clinical Challenges: MS and Pregnancy | Medpage Today - MedPage Today

    earlier this year, using data from the Kaiser Permanente Southern and Northern California databases spanning 2008 to 2016, indicated that women with MS who became pregnant did not experience increased risk of relapse after pregnancy. It wasn't so long...

    https://mschristian.org/index.php/blog/clinical-challenges-ms-and-pregnancy-medpage-today-medpage-today
  • A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis

    together with a resampling and critical appraisal approach. The framework was applied to estimate the MS prevalence for 2016 in Switzerland, for which four distinct data sources (Swiss MS registry, Swiss national MS treatment registry, MediService...

    https://mschristian.org/index.php/articles/2-uncategorised/9970-a-framework-for-estimating-the-burden-of-chronic-diseases-design-and-application-in-the-context-of-multiple-sclerosis
  • High cost of MS medicines forcing patients to take 'drastic actions' - STAT

    sclerosis patients paid $15 a month average out-of-pocket costs in 2004, but that jumped to an average of $309 a month by 2016, a 20-fold increase over a 12-year period. Patients with high-deductible plans paid an average of $661 per month compared to...

    https://mschristian.org/index.php/articles/2-uncategorised/9868-high-cost-of-ms-medicines-forcing-patients-to-take-drastic-actions-stat
  • Global Primary Progressive Multiple Sclerosis Treatment Market 2019 – F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc. - Industry Report 24

    Treatment Market 2019, with sales, revenue, and price of worldwide Primary Progressive Multiple Sclerosis Treatment, in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in...

    https://mschristian.org/index.php/articles/2-uncategorised/9323-global-primary-progressive-multiple-sclerosis-treatment-market-2019-f-hoffmann-la-roche-ltd-genzyme-corporation-glialogix-inc-industry-report-24
  • Clinical Challenges: MS and Pregnancy | Medpage Today - MedPage Today

    earlier this year, using data from the Kaiser Permanente Southern and Northern California databases spanning 2008 to 2016, indicated that women with MS who became pregnant did not experience increased risk of relapse after pregnancy. In this study, the...

    https://mschristian.org/index.php/articles/2-uncategorised/8694-clinical-challenges-ms-and-pregnancy-medpage-today-medpage-today
  • Trump’s proposed vapor ban leaves industry in state of turmoil, confusion

    to take additional action against flavored e-products. The FDA has had the authority to ban vaping flavors since 2016, however, the regulatory agency has previously resisted calls to take that step. In a separate announcement, Acting Commissioner...

    https://mschristian.org/index.php/articles/2-uncategorised/8561-trump-s-proposed-vapor-ban-leaves-industry-in-state-of-turmoil-confusion
  • How the gut influences neurologic disease

    the link between gut bacteria and biological molecules called microRNAs (miRNAs) in the brain;... read more July 13, 2016 — The microscopic organisms that live in our gut do more than help us digest food. A new study in rats bolsters a growing body of...

    https://mschristian.org/index.php/articles/2-uncategorised/4107-how-the-gut-influences-neurologic-disease
  • Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone - P&T Community

    2019. Prior to joining Avedro, Tom served as the Chief Financial Officer of Entellus Medical, Inc., from 2007 to May 2016, guiding the company through its initial public offering in 2015. Entellus was acquired by Stryker Corporation in February 2018....

    https://mschristian.org/index.php/blog/nuvaira-announces-chief-financial-officer-and-pivotal-study-milestone-p-t-community
  • The Reasons People With MS Leave Their Jobs Differs by Stage of Life, Study Finds

    their job within 10 years of their diagnosis, according to the MS International Federation’s Global MS Employment Report 2016. Just as every person experiences the symptoms and progression of MS differently, the way the disease impacts work can vary...

    https://mschristian.org/index.php/blog/the-reasons-people-with-ms-leave-their-jobs-differs-by-stage-of-life-study-finds
  • Global Primary Progressive Multiple Sclerosis Treatment Market 2019 – F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc. - Industry Report 24

    Treatment Market 2019, with sales, revenue, and price of worldwide Primary Progressive Multiple Sclerosis Treatment, in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in...

    https://mschristian.org/index.php/blog/global-primary-progressive-multiple-sclerosis-treatment-market-2019-f-hoffmann-la-roche-ltd-genzyme-corporation-glialogix-inc-industry-report-24
  • How the gut influences neurologic disease

    the link between gut bacteria and biological molecules called microRNAs (miRNAs) in the brain;... read more July 13, 2016 — The microscopic organisms that live in our gut do more than help us digest food. A new study in rats bolsters a growing body of...

    https://mschristian.org/index.php/blog/how-the-gut-influences-neurologic-disease
  • Stretching for People with MS—An Illustrated Manual (.pdf)

    showing range of motion, stretching, and balance exercises for at-home program. By Beth E. Gibson, PT. (last updated October 2016) Download Brochure................................................................................... Stay Informed....

    https://mschristian.org/index.php/blog/stretching-for-people-with-ms-an-illustrated-manual-pdf

Results 1 - 20 of 81